RNS Number : 4022I
Genedrive PLC
04 August 2023

genedrive plc
("genedrive" or the "Company")

Application for Listing

Total Voting Rights

genedrive plc (AIM:GDR), the point of care molecular diagnostics company, confirms that in order to support the further drawdown and delivery of its £5M Equity Prepayment facility that was announced on 31 March 2023, application has been made for the Admission to trading on AIM of 3,050,000 new Ordinary Shares of 1.5p each ("New Ordinary Shares"). Admission of the New Ordinary Shares ("Admission") is expected to occur on 10 August 2023. Following Admission, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares.

Following Admission the Company's issued share capital will consist of 102,099,946 Ordinary Shares of 1.5p each and this figure may be used by shareholders as the denominator for the calculations by which they should determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further details please contact:

genedrive plc David Budd: CEO / Russ Shaw: CFO	+44 (0)161 989 0245
Peel Hunt LLP (Nominated Adviser and Joint Broker) James Steel / Patrick Birkholm	+44 (0)20 7418 8900
finnCap (Joint Broker) Geoff Nash	+44 (0)20 7220 0500
Walbrook PR Ltd (Media & Investor Relations) Paul McManus / Anna Dunphy	+44 (0)20 7933 8780 or genedrive@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7876 741 001

About genedrive plc (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use

in patient stratification (genotyping), pathogen detection and other indications. The company are currently developing a genetic test for CYP2C19 metaboliser status.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

TVRNKQBDNBKDPFK